Aurinia Pharmaceuticals Inc. (AUPH)
USD 7.8
(-3.17%)
USD 7.8
(-3.17%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 170.1 Million USD | 160.0% |
| 2022 | 65.42 Million USD | 1.79% |
| 2021 | 64.27 Million USD | 14.96% |
| 2020 | 55.91 Million USD | 5.16% |
| 2019 | 53.16 Million USD | 59.72% |
| 2018 | 33.28 Million USD | 38.1% |
| 2017 | 24.1 Million USD | 14.52% |
| 2016 | 21.04 Million USD | 54.71% |
| 2015 | 13.6 Million USD | 87.07% |
| 2014 | 7.27 Million USD | -26.11% |
| 2013 | 9.84 Million USD | 56.75% |
| 2012 | 6.27 Million USD | -20.63% |
| 2011 | 7.9 Million USD | 101.05% |
| 2010 | 3.93 Million USD | -16.98% |
| 2009 | 4.73 Million USD | -74.78% |
| 2008 | 18.78 Million USD | 31.82% |
| 2007 | 14.25 Million USD | 36.12% |
| 2006 | 10.47 Million USD | -12.69% |
| 2005 | 11.99 Million USD | 33.65% |
| 2004 | 8.97 Million USD | 52.33% |
| 2003 | 5.89 Million USD | 88.8% |
| 2002 | 3.12 Million USD | 75.33% |
| 2001 | 1.77 Million USD | 47.12% |
| 2000 | 1.2 Million USD | 27.22% |
| 1999 | 950.73 Thousand USD | -60.53% |
| 1998 | 2.4 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 157.15 Million USD | -7.61% |
| 2024 Q2 | 158.91 Million USD | 1.12% |
| 2023 Q3 | 163.13 Million USD | 4.17% |
| 2023 FY | 170.1 Million USD | 160.0% |
| 2023 Q4 | 170.1 Million USD | 4.27% |
| 2023 Q1 | 61.35 Million USD | -6.22% |
| 2023 Q2 | 156.6 Million USD | 155.26% |
| 2022 Q1 | 58.77 Million USD | -8.55% |
| 2022 Q2 | 58.38 Million USD | -0.68% |
| 2022 Q3 | 64.86 Million USD | 11.11% |
| 2022 Q4 | 65.42 Million USD | 0.86% |
| 2022 FY | 65.42 Million USD | 1.79% |
| 2021 Q3 | 61.89 Million USD | 14.6% |
| 2021 FY | 64.27 Million USD | 14.96% |
| 2021 Q1 | 46.85 Million USD | -16.21% |
| 2021 Q2 | 54.01 Million USD | 15.28% |
| 2021 Q4 | 64.27 Million USD | 3.85% |
| 2020 Q3 | 62.9 Million USD | 11.86% |
| 2020 Q2 | 56.23 Million USD | 9.07% |
| 2020 Q4 | 55.91 Million USD | -11.12% |
| 2020 FY | 55.91 Million USD | 5.16% |
| 2020 Q1 | 51.56 Million USD | -3.02% |
| 2019 Q3 | 27.1 Million USD | 6.84% |
| 2019 Q1 | 25.15 Million USD | -24.43% |
| 2019 Q4 | 53.16 Million USD | 96.17% |
| 2019 FY | 53.16 Million USD | 59.72% |
| 2019 Q2 | 25.36 Million USD | 0.85% |
| 2018 Q2 | 25.68 Million USD | 7.22% |
| 2018 FY | 33.28 Million USD | 38.1% |
| 2018 Q3 | 32.35 Million USD | 25.96% |
| 2018 Q4 | 33.28 Million USD | 2.89% |
| 2018 Q1 | 23.95 Million USD | -0.61% |
| 2017 Q1 | 47.03 Million USD | 123.46% |
| 2017 Q2 | 29.33 Million USD | -37.63% |
| 2017 Q4 | 24.1 Million USD | -25.11% |
| 2017 Q3 | 32.18 Million USD | 9.73% |
| 2017 FY | 24.1 Million USD | 14.52% |
| 2016 Q2 | 10.64 Million USD | -9.19% |
| 2016 FY | 21.04 Million USD | 54.71% |
| 2016 Q1 | 11.72 Million USD | -13.82% |
| 2016 Q3 | 13.14 Million USD | 23.48% |
| 2016 Q4 | 21.04 Million USD | 60.09% |
| 2015 Q3 | 15.4 Million USD | -5.89% |
| 2015 Q2 | 16.37 Million USD | -19.95% |
| 2015 Q1 | 20.44 Million USD | 181.2% |
| 2015 FY | 13.6 Million USD | 87.07% |
| 2015 Q4 | 13.6 Million USD | -11.69% |
| 2014 Q3 | 7.07 Million USD | -22.26% |
| 2014 FY | 7.27 Million USD | -26.11% |
| 2014 Q2 | 9.1 Million USD | 5.21% |
| 2014 Q1 | 8.65 Million USD | -12.06% |
| 2014 Q4 | 7.27 Million USD | 2.73% |
| 2013 Q2 | 6.76 Million USD | 3.09% |
| 2013 Q1 | 6.56 Million USD | 4.57% |
| 2013 FY | 9.84 Million USD | 56.75% |
| 2013 Q4 | 9.84 Million USD | -11.32% |
| 2013 Q3 | 11.09 Million USD | 63.97% |
| 2012 Q3 | 5.53 Million USD | 5.75% |
| 2012 Q2 | 5.23 Million USD | 46.04% |
| 2012 Q1 | 3.58 Million USD | -54.71% |
| 2012 FY | 6.27 Million USD | -20.63% |
| 2012 Q4 | 6.27 Million USD | 13.49% |
| 2011 Q3 | 7.65 Million USD | -10.13% |
| 2011 Q2 | 8.51 Million USD | -7.69% |
| 2011 Q1 | 9.22 Million USD | 134.55% |
| 2011 FY | 7.9 Million USD | 101.05% |
| 2011 Q4 | 7.9 Million USD | 3.32% |
| 2010 Q3 | 4.44 Million USD | 57.45% |
| 2010 Q1 | 3.85 Million USD | -18.75% |
| 2010 FY | 3.93 Million USD | -16.98% |
| 2010 Q4 | 3.93 Million USD | -11.52% |
| 2010 Q2 | 2.82 Million USD | -26.65% |
| 2009 Q4 | 4.73 Million USD | 0.1% |
| 2009 FY | 4.73 Million USD | -74.78% |
| 2009 Q3 | 4.73 Million USD | 34.14% |
| 2009 Q2 | 3.52 Million USD | -60.75% |
| 2009 Q1 | 8.99 Million USD | -52.14% |
| 2008 Q1 | 7.93 Million USD | -44.31% |
| 2008 FY | 18.78 Million USD | 31.82% |
| 2008 Q3 | 19.76 Million USD | -7.6% |
| 2008 Q4 | 18.78 Million USD | -4.95% |
| 2008 Q2 | 21.39 Million USD | 169.53% |
| 2007 Q2 | 12.67 Million USD | 24.1% |
| 2007 FY | 14.25 Million USD | 36.12% |
| 2007 Q4 | 14.25 Million USD | 27.23% |
| 2007 Q3 | 11.2 Million USD | -11.62% |
| 2007 Q1 | 10.21 Million USD | -2.45% |
| 2006 Q1 | 9.93 Million USD | -17.14% |
| 2006 Q4 | 10.47 Million USD | -5.95% |
| 2006 Q3 | 11.13 Million USD | 3.73% |
| 2006 FY | 10.47 Million USD | -12.69% |
| 2006 Q2 | 10.73 Million USD | 8.0% |
| 2005 Q3 | 8.88 Million USD | 26.09% |
| 2005 Q1 | 7.23 Million USD | -19.38% |
| 2005 FY | 11.99 Million USD | 33.65% |
| 2005 Q4 | 11.99 Million USD | 35.01% |
| 2005 Q2 | 7.04 Million USD | -2.62% |
| 2004 Q4 | 8.97 Million USD | 13.92% |
| 2004 Q3 | 7.87 Million USD | 145.92% |
| 2004 FY | 8.97 Million USD | 52.33% |
| 2004 Q2 | 3.2 Million USD | -42.63% |
| 2004 Q1 | 5.58 Million USD | -5.22% |
| 2003 Q1 | 3.04 Million USD | -2.28% |
| 2003 FY | 5.89 Million USD | 88.8% |
| 2003 Q3 | 4.03 Million USD | 6.03% |
| 2003 Q4 | 5.89 Million USD | 46.05% |
| 2003 Q2 | 3.8 Million USD | 24.77% |
| 2002 FY | 3.12 Million USD | 75.33% |
| 2002 Q3 | 3.13 Million USD | -25.85% |
| 2002 Q1 | 1.95 Million USD | 0.0% |
| 2002 Q2 | 4.22 Million USD | 116.35% |
| 2002 Q4 | 3.12 Million USD | -0.49% |
| 2001 Q2 | 1.12 Million USD | 27.07% |
| 2001 Q3 | 4.03 Million USD | 259.37% |
| 2001 Q1 | 884.43 Thousand USD | -26.88% |
| 2001 FY | 1.77 Million USD | 47.12% |
| 2000 Q2 | 1 Million USD | 32.06% |
| 2000 Q3 | 818.13 Thousand USD | -18.28% |
| 2000 Q1 | 758.06 Thousand USD | -20.27% |
| 2000 Q4 | 1.2 Million USD | 47.84% |
| 2000 FY | 1.2 Million USD | 27.22% |
| 1999 Q3 | 1 Million USD | -45.19% |
| 1999 Q2 | 1.83 Million USD | 6.24% |
| 1999 Q1 | 1.72 Million USD | 0.0% |
| 1999 Q4 | 950.73 Thousand USD | -5.27% |
| 1999 FY | 950.73 Thousand USD | -60.53% |
| 1998 FY | 2.4 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| AbCellera Biologics Inc. | 335.77 Million USD | 49.339% |
| Alkermes plc | 933.53 Million USD | 81.778% |
| Agenus Inc. | 462.29 Million USD | 63.204% |
| Alnylam Pharmaceuticals, Inc. | 4.05 Billion USD | 95.8% |
| Aptorum Group Limited | 5.25 Million USD | -3135.999% |
| Ardelyx, Inc. | 130.76 Million USD | -30.089% |
| Arrowhead Pharmaceuticals, Inc. | 478.39 Million USD | 64.442% |
| Bicycle Therapeutics plc | 224.41 Million USD | 24.198% |
| BioXcel Therapeutics, Inc. | 130.21 Million USD | -30.641% |
| ChromaDex Corporation | 26.5 Million USD | -541.723% |
| Chimerix, Inc. | 19.74 Million USD | -761.524% |
| Corbus Pharmaceuticals Holdings, Inc. | 35.17 Million USD | -383.576% |
| Caribou Biosciences, Inc. | 72.56 Million USD | -134.415% |
| CRISPR Therapeutics AG | 346.76 Million USD | 50.945% |
| Precision BioSciences, Inc. | 140.92 Million USD | -20.712% |
| Dyadic International, Inc. | 2.34 Million USD | -7167.551% |
| Eton Pharmaceuticals, Inc. | 16.26 Million USD | -945.982% |
| Fortress Biotech, Inc. | 165.93 Million USD | -2.512% |
| Lantern Pharma Inc. | 2.73 Million USD | -6109.042% |
| HOOKIPA Pharma Inc. | 71.48 Million USD | -137.98% |
| Inhibikase Therapeutics, Inc. | 3.52 Million USD | -4720.665% |
| Incyte Corporation | 1.59 Billion USD | 89.317% |
| IO Biotech, Inc. | 17.55 Million USD | -868.945% |
| Jaguar Health, Inc. | 45.86 Million USD | -270.88% |
| Novavax, Inc. | 2.57 Billion USD | 93.387% |
| Janux Therapeutics, Inc. | 36.05 Million USD | -371.762% |
| Opthea Limited | 264.6 Million USD | 35.712% |
| Ligand Pharmaceuticals Incorporated | 130.7 Million USD | -30.145% |
| ContextLogic Inc. | 206 Million USD | 17.423% |
| MiMedx Group, Inc. | 96.33 Million USD | -76.589% |
| Pyxis Oncology, Inc. | 48.02 Million USD | -254.229% |
| TransCode Therapeutics, Inc. | 3.52 Million USD | -4720.443% |
| NextCure, Inc. | 14.99 Million USD | -1034.28% |
| Ocuphire Pharma, Inc. | 4.04 Million USD | -4108.511% |
| Oncternal Therapeutics, Inc. | 6.67 Million USD | -2447.671% |
| Outlook Therapeutics, Inc. | 46.73 Million USD | -263.953% |
| Vaxcyte, Inc. | 167.44 Million USD | -1.588% |
| PDS Biotechnology Corporation | 33.25 Million USD | -411.463% |
| Madrigal Pharmaceuticals, Inc. | 235.21 Million USD | 27.679% |
| Pharming Group N.V. | 244.07 Million USD | 30.304% |
| Pieris Pharmaceuticals, Inc. | 11.92 Million USD | -1326.841% |
| Avidity Biosciences, Inc. | 127.79 Million USD | -33.114% |
| Reviva Pharmaceuticals Holdings, Inc. | 6.6 Million USD | -2474.555% |
| Reviva Pharmaceuticals Holdings, Inc. | 6.6 Million USD | -2474.555% |
| Sangamo Therapeutics, Inc. | 82.43 Million USD | -106.359% |
| Sol-Gel Technologies Ltd. | 6.64 Million USD | -2460.711% |
| Acelyrin, Inc. | 86.35 Million USD | -96.991% |
| Salarius Pharmaceuticals, Inc. | 1.29 Million USD | -12992.875% |
| SELLAS Life Sciences Group, Inc. | 14.37 Million USD | -1083.031% |
| Summit Therapeutics Inc. | 125.25 Million USD | -35.807% |
| Sensei Biotherapeutics, Inc. | 9.47 Million USD | -1694.577% |
| Senti Biosciences, Inc. | 52.57 Million USD | -223.578% |
| Stoke Therapeutics, Inc. | 68.77 Million USD | -147.333% |
| Syros Pharmaceuticals, Inc. | 151.51 Million USD | -12.274% |
| Alaunos Therapeutics, Inc. | 1.95 Million USD | -8596.728% |
| Telomir Pharmaceuticals, Inc. Common Stock | 1.33 Million USD | -12636.791% |
| Entrada Therapeutics, Inc. | 226.83 Million USD | 25.007% |
| VistaGen Therapeutics, Inc. | 9.36 Million USD | -1716.035% |
| Wave Life Sciences Ltd. | 227.44 Million USD | 25.209% |
| Sorrento Therapeutics, Inc. | 494.5 Million USD | 65.601% |
| TRACON Pharmaceuticals, Inc. | 10.91 Million USD | -1458.622% |
| Barinthus Biotherapeutics plc | 27.51 Million USD | -518.327% |
| Psyence Biomedical Ltd. | 12.1 Million USD | -1305.305% |
| Phathom Pharmaceuticals, Inc. | 486.6 Million USD | 65.042% |
| Immix Biopharma, Inc. | 3.72 Million USD | -4470.605% |
| Keros Therapeutics, Inc. | 37.81 Million USD | -349.878% |
| MEI Pharma, Inc. | 8.35 Million USD | -1936.002% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | -486.276% |
| Xeris Biopharma Holdings, Inc. | 347.58 Million USD | 51.059% |
| Rigel Pharmaceuticals, Inc. | 145.86 Million USD | -16.617% |
| Fortress Biotech, Inc. | 165.93 Million USD | -2.512% |
| Precigen, Inc. | 41.64 Million USD | -308.481% |
| Clearside Biomedical, Inc. | 49.93 Million USD | -240.693% |
| AlloVir, Inc. | 45.01 Million USD | -277.892% |
| C4 Therapeutics, Inc. | 130.33 Million USD | -30.514% |
| Fate Therapeutics, Inc. | 137.8 Million USD | -23.446% |
| ImmuCell Corporation | 18.81 Million USD | -804.107% |
| IDEAYA Biosciences, Inc. | 28.22 Million USD | -502.664% |
| Onconetix, Inc. | 23.18 Million USD | -633.829% |
| PureTech Health plc | 125.58 Million USD | -35.455% |
| VYNE Therapeutics Inc. | 8.95 Million USD | -1800.648% |
| Elevation Oncology, Inc. | 34.28 Million USD | -396.202% |
| Kintara Therapeutics, Inc. | 2.44 Million USD | -6857.382% |
| Seer, Inc. | 39.36 Million USD | -332.13% |
| Verrica Pharmaceuticals Inc. | 61.83 Million USD | -175.104% |
| Innoviva, Inc. | 568.55 Million USD | 70.08% |
| Aadi Bioscience, Inc. | 27.22 Million USD | -524.754% |
| ESSA Pharma Inc. | 3.49 Million USD | -4767.083% |
| GlycoMimetics, Inc. | 6.9 Million USD | -2364.593% |
| GT Biopharma, Inc. | 6.63 Million USD | -2464.571% |
| Inhibrx Biosciences, Inc. | 264.39 Million USD | 35.66% |
| Akebia Therapeutics, Inc. | 272.28 Million USD | 37.526% |
| Catalyst Pharmaceuticals, Inc. | 84.02 Million USD | -102.447% |
| Longboard Pharmaceuticals, Inc. | 9.77 Million USD | -1640.413% |
| Orchestra BioMed Holdings, Inc. | 27.16 Million USD | -526.111% |
| Alzamend Neuro, Inc. | 3.22 Million USD | -5173.403% |
| Rocket Pharmaceuticals, Inc. | 73.76 Million USD | -130.602% |
| Aptose Biosciences Inc. | 15.8 Million USD | -976.04% |
| ZyVersa Therapeutics, Inc. | 11.03 Million USD | -1440.877% |
| Soligenix, Inc. | 7.27 Million USD | -2238.285% |
| Century Therapeutics, Inc. | 175.94 Million USD | 3.315% |
| Kura Oncology, Inc. | 51.66 Million USD | -229.271% |
| TScan Therapeutics, Inc. | 121.28 Million USD | -40.258% |
| Intensity Therapeutics, Inc. | 4.13 Million USD | -4015.848% |
| Ocean Biomedical, Inc. | 6.61 Million USD | -2471.995% |
| CytomX Therapeutics, Inc. | 252.59 Million USD | 32.657% |
| Autolus Therapeutics plc | 263.9 Million USD | 35.542% |
| Mineralys Therapeutics, Inc. | 10.48 Million USD | -1522.858% |
| EyePoint Pharmaceuticals, Inc. | 88.86 Million USD | -91.432% |
| Eterna Therapeutics Inc. | 46.89 Million USD | -262.711% |
| Adaptive Biotechnologies Corporation | 352.85 Million USD | 51.791% |
| GRI Bio, Inc. | 2.69 Million USD | -6207.304% |
| Xenetic Biosciences, Inc. | 809.58 Thousand USD | -20911.753% |
| Tenaya Therapeutics, Inc. | 31.09 Million USD | -447.129% |
| IGM Biosciences, Inc. | 220.17 Million USD | 22.74% |
| INmune Bio, Inc. | 18.86 Million USD | -801.856% |
| Heron Therapeutics, Inc. | 256.47 Million USD | 33.676% |
| SAB Biotherapeutics, Inc. | 26.64 Million USD | -538.5% |
| Pasithea Therapeutics Corp. | 2.71 Million USD | -6157.638% |
| Entero Therapeutics, Inc. | 3.28 Million USD | -5085.799% |
| Milestone Pharmaceuticals Inc. | 58.45 Million USD | -191.007% |
| X4 Pharmaceuticals, Inc. | 96.15 Million USD | -76.903% |
| Atara Biotherapeutics, Inc. | 264.73 Million USD | 35.744% |
| Coherus BioSciences, Inc. | 823.02 Million USD | 79.331% |
| Verastem, Inc. | 71.18 Million USD | -138.966% |
| Abeona Therapeutics Inc. | 49.17 Million USD | -245.917% |
| Pliant Therapeutics, Inc. | 38.57 Million USD | -340.946% |
| Tonix Pharmaceuticals Holding Corp. | 48.93 Million USD | -247.642% |
| Histogen Inc. | 5.69 Million USD | -2885.922% |
| Aprea Therapeutics, Inc. | 4.38 Million USD | -3778.781% |
| Surrozen, Inc. | 8.14 Million USD | -1988.496% |
| Organovo Holdings, Inc. | 2.74 Million USD | -6090.247% |
| Lixte Biotechnology Holdings, Inc. | 313.85 Thousand USD | -54099.033% |
| Ovid Therapeutics Inc. | 56.22 Million USD | -202.522% |
| Panbela Therapeutics, Inc. | 16.51 Million USD | -930.208% |
| CASI Pharmaceuticals, Inc. | 51.1 Million USD | -232.873% |
| Cadrenal Therapeutics, Inc. Common Stock | 826.87 Thousand USD | -20472.396% |
| Centessa Pharmaceuticals plc | 126.72 Million USD | -34.234% |
| Hepion Pharmaceuticals, Inc. | 10.81 Million USD | -1473.095% |
| Arcturus Therapeutics Holdings Inc. | 150.88 Million USD | -12.737% |
| BioRestorative Therapies, Inc. | 2.6 Million USD | -6424.185% |
| Apollomics, Inc. | 14.15 Million USD | -1101.922% |
| Amarin Corporation plc | 279.58 Million USD | 39.157% |
| Mesoblast Limited | 188.79 Million USD | 9.899% |
| Turnstone Biologics Corp. | 14.14 Million USD | -1102.347% |
| Kymera Therapeutics, Inc. | 180.78 Million USD | 5.907% |
| Synaptogenix, Inc. | 5.52 Million USD | -2976.389% |
| Tiziana Life Sciences Ltd | 6.64 Million USD | -2458.785% |
| BriaCell Therapeutics Corp. | 8.55 Million USD | -1887.895% |
| Monopar Therapeutics Inc. | 1.75 Million USD | -9579.565% |
| Exelixis, Inc. | 678.44 Million USD | 74.927% |
| Better Therapeutics, Inc. | 23.84 Million USD | -613.48% |
| Nurix Therapeutics, Inc. | 164.04 Million USD | -3.695% |
| Apellis Pharmaceuticals, Inc. | 594.2 Million USD | 71.372% |
| NLS Pharmaceutics AG | 10.68 Million USD | -1492.741% |
| Dermata Therapeutics, Inc. | 1.62 Million USD | -10377.108% |
| Aridis Pharmaceuticals, Inc. | 38.92 Million USD | -336.992% |
| Gritstone bio, Inc. | 125.91 Million USD | -35.093% |
| Jasper Therapeutics, Inc. | 14.67 Million USD | -1059.09% |
| TNF Pharmaceuticals, Inc. | 5.08 Million USD | -3242.906% |
| Avid Bioservices, Inc. | 275.66 Million USD | 38.292% |
| Insmed Incorporated | 1.66 Billion USD | 89.763% |
| Virpax Pharmaceuticals, Inc. | 7.69 Million USD | -2110.911% |
| MediWound Ltd. | 27.18 Million USD | -525.696% |
| OmniAb, Inc. | 87.4 Million USD | -94.632% |
| Alector, Inc. | 487.66 Million USD | 65.118% |
| Seres Therapeutics, Inc. | 403.45 Million USD | 57.837% |
| Checkpoint Therapeutics, Inc. | 18.42 Million USD | -823.246% |
| Viracta Therapeutics, Inc. | 38.37 Million USD | -343.301% |
| Zai Lab Limited | 240.17 Million USD | 29.174% |
| Revance Therapeutics, Inc. | 630.05 Million USD | 73.001% |
| Aura Biosciences, Inc. | 29.22 Million USD | -482.023% |
| Lyell Immunopharma, Inc. | 95.07 Million USD | -78.916% |
| Immunic, Inc. | 25.36 Million USD | -570.561% |
| Tarsus Pharmaceuticals, Inc. | 69.23 Million USD | -145.693% |
| Veracyte, Inc. | 93.71 Million USD | -81.509% |
| InMed Pharmaceuticals Inc. | 2.61 Million USD | -6400.927% |
| FibroGen, Inc. | 585.72 Million USD | 70.958% |
| SeaStar Medical Holding Corporation | 17.38 Million USD | -878.588% |
| Adial Pharmaceuticals, Inc. | 653.07 Thousand USD | -25947.198% |
| Sonnet BioTherapeutics Holdings, Inc. | 5.65 Million USD | -2907.855% |
| Jazz Pharmaceuticals plc | 7.65 Billion USD | 97.778% |
| Cyclacel Pharmaceuticals, Inc. | 8.19 Million USD | -1974.994% |
| Amylyx Pharmaceuticals, Inc. | 84.02 Million USD | -102.456% |
| TG Therapeutics, Inc. | 169.08 Million USD | -0.605% |
| Galecto, Inc. | 5.89 Million USD | -2785.142% |
| Calithera Biosciences, Inc. | 8.28 Million USD | -1953.452% |
| Fortrea Holdings Inc. | 2.61 Billion USD | 93.503% |
| KalVista Pharmaceuticals, Inc. | 28.82 Million USD | -490.202% |
| Aptevo Therapeutics Inc. | 12.62 Million USD | -1247.817% |
| XBiotech Inc. | 8.39 Million USD | -1925.819% |
| Jasper Therapeutics, Inc. | 14.67 Million USD | -1059.09% |
| Lyra Therapeutics, Inc. | 53.18 Million USD | -219.872% |
| Foghorn Therapeutics Inc. | 363.1 Million USD | 53.152% |
| Y-mAbs Therapeutics, Inc. | 26.88 Million USD | -532.748% |
| Theravance Biopharma, Inc. | 169 Million USD | -0.653% |
| Ultragenyx Pharmaceutical Inc. | 1.21 Billion USD | 86.006% |
| Metagenomi, Inc. Common Stock | 500.42 Million USD | 66.007% |
| Vaxxinity, Inc. | 30.94 Million USD | -449.729% |
| BioCryst Pharmaceuticals, Inc. | 972.48 Million USD | 82.508% |
| Gain Therapeutics, Inc. | 6.03 Million USD | -2720.51% |
| Cartesian Therapeutics, Inc. | 745.23 Million USD | 77.174% |
| NexImmune, Inc. | 5.08 Million USD | -3245.795% |
| Creative Medical Technology Holdings, Inc. | 371.39 Thousand USD | -45702.571% |
| Marker Therapeutics, Inc. | 3.07 Million USD | -5432.241% |
| Regeneron Pharmaceuticals, Inc. | 7.1 Billion USD | 97.607% |
| Chemomab Therapeutics Ltd. | 5.15 Million USD | -3200.485% |
| Scopus BioPharma Inc. | 7.45 Million USD | -2181.971% |
| RAPT Therapeutics, Inc. | 26.29 Million USD | -546.946% |
| Ainos, Inc. | 7.39 Million USD | -2200.553% |
| Pluri Inc. | 34.11 Million USD | -398.675% |
| Prothena Corporation plc | 135.01 Million USD | -25.99% |
| Adaptimmune Therapeutics plc | 243.1 Million USD | 30.026% |
| Celularity Inc. | 102.92 Million USD | -65.267% |
| Rallybio Corporation | 9.43 Million USD | -1702.755% |
| Cue Biopharma, Inc. | 24.44 Million USD | -595.881% |
| MeiraGTx Holdings plc | 319.99 Million USD | 46.84% |
| Omeros Corporation | 403.25 Million USD | 57.816% |
| Humacyte, Inc. | 114.67 Million USD | -48.337% |
| Immunocore Holdings plc | 228.15 Million USD | 25.443% |
| Cocrystal Pharma, Inc. | 4.87 Million USD | -3389.395% |
| Cidara Therapeutics, Inc. | 76.74 Million USD | -121.668% |
| Blueprint Medicines Corporation | 918.64 Million USD | 81.483% |
| CalciMedica, Inc. | 4.02 Million USD | -4123.138% |
| Cabaletta Bio, Inc. | 17.45 Million USD | -874.719% |
| Marinus Pharmaceuticals, Inc. | 154.14 Million USD | -10.357% |
| Scholar Rock Holding Corporation | 85.81 Million USD | -98.222% |
| Sana Biotechnology, Inc. | 277.79 Million USD | 38.764% |
| Pulmatrix, Inc. | 15.96 Million USD | -965.639% |
| Elicio Therapeutics, Inc. | 15.77 Million USD | -978.476% |
| Vigil Neuroscience, Inc. | 24.6 Million USD | -591.327% |
| Intellia Therapeutics, Inc. | 250.8 Million USD | 32.176% |
| Adlai Nortye Ltd. American Depositary Shares | 50.78 Million USD | -234.951% |
| Cytokinetics, Incorporated | 1.21 Billion USD | 85.949% |
| Eloxx Pharmaceuticals, Inc. | 31.78 Million USD | -435.217% |
| Nutriband Inc. | 1.07 Million USD | -15666.522% |
| Protara Therapeutics, Inc. | 10.63 Million USD | -1499.812% |
| Vor Biopharma Inc. | 59.1 Million USD | -187.811% |
| Roivant Sciences Ltd. | 773.95 Million USD | 78.021% |
| Evogene Ltd. | 17.99 Million USD | -845.57% |
| ProKidney Corp. | 29.21 Million USD | -482.243% |
| Applied Therapeutics, Inc. | 71.97 Million USD | -136.33% |
| Hoth Therapeutics, Inc. | 704.98 Thousand USD | -24029.376% |
| BridgeBio Pharma, Inc. | 1.88 Billion USD | 90.994% |
| CorMedix Inc. | 11.91 Million USD | -1327.377% |
| BioLineRx Ltd. | 50.7 Million USD | -235.506% |
| Tango Therapeutics, Inc. | 149.45 Million USD | -13.816% |
| Galectin Therapeutics Inc. | 88.44 Million USD | -92.341% |
| Atai Life Sciences N.V. | 49.16 Million USD | -246.015% |
| Renovaro Biosciences Inc. | 31.15 Million USD | -446.053% |
| Aerovate Therapeutics, Inc. | 17.96 Million USD | -847.044% |
| Zentalis Pharmaceuticals, Inc. | 124.63 Million USD | -36.484% |
| Sagimet Biosciences Inc. | 5.65 Million USD | -2908.631% |
| MediciNova, Inc. | 3.89 Million USD | -4271.211% |
| Praxis Precision Medicines, Inc. | 18.27 Million USD | -830.62% |
| Cardio Diagnostics Holdings, Inc. | 1.5 Million USD | -11208.56% |
| GeoVax Labs, Inc. | 3.51 Million USD | -4732.777% |
| Axsome Therapeutics, Inc. | 397.25 Million USD | 57.18% |
| Biomea Fusion, Inc. | 30.69 Million USD | -454.278% |
| PTC Therapeutics, Inc. | 2.72 Billion USD | 93.75% |
| Mereo BioPharma Group plc | 15.96 Million USD | -965.706% |
| Cullinan Oncology, Inc. | 31.2 Million USD | -445.2% |
| Syndax Pharmaceuticals, Inc. | 58.68 Million USD | -189.871% |
| Absci Corporation | 58.3 Million USD | -191.76% |
| NRx Pharmaceuticals, Inc. | 19.04 Million USD | -793.049% |
| 4D Molecular Therapeutics, Inc. | 32.06 Million USD | -430.56% |
| Dyne Therapeutics, Inc. | 73.79 Million USD | -130.53% |
| Kiniksa Pharmaceuticals, Ltd. | 87.48 Million USD | -94.447% |
| Ventyx Biosciences, Inc. | 33.77 Million USD | -403.725% |
| Allakos Inc. | 74.79 Million USD | -127.438% |
| Imunon, Inc. | 8.53 Million USD | -1894.132% |
| Fulcrum Therapeutics, Inc. | 22.5 Million USD | -656.002% |
| Corcept Therapeutics Incorporated | 114.81 Million USD | -48.162% |
| BioAtla, Inc. | 48.98 Million USD | -247.258% |
| NLS Pharmaceutics AG | 10.68 Million USD | -1492.741% |
| Bio-Path Holdings, Inc. | 2.77 Million USD | -6021.195% |
| Allogene Therapeutics, Inc. | 130.6 Million USD | -30.247% |
| Larimar Therapeutics, Inc. | 14.21 Million USD | -1096.68% |
| XOMA Corporation | 145.58 Million USD | -16.848% |
| Kezar Life Sciences, Inc. | 33.66 Million USD | -405.296% |
| Cara Therapeutics, Inc. | 68.75 Million USD | -147.397% |
| aTyr Pharma, Inc. | 31.59 Million USD | -438.368% |
| Aligos Therapeutics, Inc. | 61.82 Million USD | -175.153% |
| Akero Therapeutics, Inc. | 44.96 Million USD | -278.312% |
| Viridian Therapeutics, Inc. | 48.4 Million USD | -251.448% |
| Eliem Therapeutics, Inc. | 2.87 Million USD | -5827.108% |
| EyeGate Pharmaceuticals, Inc. | 8.15 Million USD | -1985.163% |
| Akari Therapeutics, Plc | 4.58 Million USD | -3610.908% |
| Tevogen Bio Holdings Inc. | 17.73 Million USD | -859.267% |
| Halozyme Therapeutics, Inc. | 1.64 Billion USD | 89.687% |
| Lexaria Bioscience Corp. | 403.9 Thousand USD | -42015.531% |
| UroGen Pharma Ltd. | 243.52 Million USD | 30.147% |
| Sutro Biopharma, Inc. | 321.08 Million USD | 47.021% |
| ZIVO Bioscience, Inc. | 2.76 Million USD | -6059.856% |
| Orgenesis Inc. | 35.53 Million USD | -378.706% |
| Entera Bio Ltd. | 1.37 Million USD | -12235.606% |
| GH Research PLC | 6.7 Million USD | -2438.546% |
| Lisata Therapeutics, Inc. | 6.8 Million USD | -2401.588% |
| Reneo Pharmaceuticals, Inc. | 18.82 Million USD | -803.58% |
| Xencor, Inc. | 283.55 Million USD | 40.01% |
| 60 Degrees Pharmaceuticals, Inc. | 2.98 Million USD | -5597.472% |
| Replimune Group, Inc. | 113.21 Million USD | -50.254% |
| Coeptis Therapeutics Holdings, Inc. | 3.75 Million USD | -4427.611% |
| Vanda Pharmaceuticals Inc. | 103.53 Million USD | -64.308% |
| Lexaria Bioscience Corp. | 403.9 Thousand USD | -42015.531% |
| Portage Biotech Inc. | 4.45 Million USD | -3722.652% |
| Cardio Diagnostics Holdings, Inc. | 1.5 Million USD | -11208.56% |
| Olema Pharmaceuticals, Inc. | 23.05 Million USD | -637.996% |
| OncoCyte Corporation | 49.29 Million USD | -245.061% |
| Qualigen Therapeutics, Inc. | 4.13 Million USD | -4012.062% |
| Processa Pharmaceuticals, Inc. | 797.48 Thousand USD | -21230.585% |
| Purple Biotech Ltd. | 10 Million USD | -1600.23% |
| CollPlant Biotechnologies Ltd. | 5.78 Million USD | -2839.993% |
| scPharmaceuticals Inc. | 57.26 Million USD | -197.075% |
| ProMIS Neurosciences, Inc. | 12.38 Million USD | -1273.165% |
| HilleVax, Inc. | 78.9 Million USD | -115.575% |
| NeuroSense Therapeutics Ltd. | 5.05 Million USD | -3268.475% |
| Tharimmune, Inc. | 1.81 Million USD | -9272.104% |
| Genprex, Inc. | 3.25 Million USD | -5127.324% |
| Neumora Therapeutics, Inc. Common Stock | 27.11 Million USD | -527.265% |
| Atossa Therapeutics, Inc. | 5.23 Million USD | -3148.816% |
| XTL Biopharmaceuticals Ltd. | 206 Thousand USD | -82476.699% |
| Virios Therapeutics, Inc. | 358.54 Thousand USD | -47343.578% |
| OKYO Pharma Limited | 7.42 Million USD | -2192.299% |
| Savara Inc. | 37.19 Million USD | -357.378% |
| Curis, Inc. | 57.61 Million USD | -195.265% |
| Daré Bioscience, Inc. | 26.32 Million USD | -546.065% |
| Carmell Therapeutics Corporation | 39.19 Million USD | -333.951% |
| Titan Pharmaceuticals, Inc. | 1.44 Million USD | -11680.332% |
| Achieve Life Sciences, Inc. | 20.81 Million USD | -717.081% |
| BeiGene, Ltd. | 2.23 Billion USD | 92.385% |
| Kiromic BioPharma, Inc. | 21.28 Million USD | -699.012% |
| Revolution Medicines, Inc. Warrant | 262.39 Million USD | 35.172% |
| Protagonist Therapeutics, Inc. | 21.27 Million USD | -699.605% |
| Erasca, Inc. | 78.61 Million USD | -116.392% |
| bluebird bio, Inc. | 424.62 Million USD | 59.939% |
| Protagenic Therapeutics, Inc. | 655.25 Thousand USD | -25860.699% |
| BioMarin Pharmaceutical Inc. | 1.89 Billion USD | 91.0% |
| DBV Technologies S.A. | 42.8 Million USD | -297.449% |
| Protagenic Therapeutics, Inc. | 655.25 Thousand USD | -25860.699% |
| Moderna, Inc. | 4.57 Billion USD | 96.279% |
| Vincerx Pharma, Inc. | 6.99 Million USD | -2331.851% |
| Fresh Tracks Therapeutics, Inc. | 1.65 Million USD | -10172.222% |
| Molecular Templates, Inc. | 31.17 Million USD | -445.725% |
| Acrivon Therapeutics, Inc. Common Stock | 17.07 Million USD | -896.532% |
| Travere Therapeutics, Inc. | 588.1 Million USD | 71.075% |
| Monte Rosa Therapeutics, Inc. | 124.5 Million USD | -36.627% |
| Spruce Biosciences, Inc. | 27.43 Million USD | -519.995% |
| Celldex Therapeutics, Inc. | 36.45 Million USD | -366.612% |
| Cogent Biosciences, Inc. | 55.63 Million USD | -205.757% |
| MacroGenics, Inc. | 154.2 Million USD | -10.311% |
| RenovoRx, Inc. | 4.46 Million USD | -3708.957% |
| Adicet Bio, Inc. | 37.12 Million USD | -358.265% |
| Prime Medicine, Inc. | 60.78 Million USD | -179.875% |
| Aditxt, Inc. | 28.53 Million USD | -496.21% |
| Adagene Inc. | 45.16 Million USD | -276.601% |
| Estrella Immunopharma, Inc. | 180.7 Thousand USD | -94037.83% |
| Quantum-Si incorporated | 26.63 Million USD | -538.759% |
| Maravai LifeSciences Holdings, Inc. | 697.56 Million USD | 75.614% |
| Acurx Pharmaceuticals, Inc. | 3.04 Million USD | -5491.174% |
| Voyager Therapeutics, Inc. | 114.96 Million USD | -47.97% |
| SciSparc Ltd. | 1.59 Million USD | -10565.078% |
| Vericel Corporation | 127.7 Million USD | -33.204% |
| Revelation Biosciences, Inc. | 5.56 Million USD | -2956.806% |
| Minerva Neurosciences, Inc. | 85.35 Million USD | -99.287% |
| Generation Bio Co. | 171.63 Million USD | 0.887% |
| Astria Therapeutics, Inc. | 11.55 Million USD | -1372.797% |
| Black Diamond Therapeutics, Inc. | 41.83 Million USD | -306.655% |
| Arcutis Biotherapeutics, Inc. | 252.69 Million USD | 32.683% |
| Invivyd, Inc. | 51.71 Million USD | -228.946% |
| Relay Therapeutics, Inc. | 91.97 Million USD | -84.946% |
| Quoin Pharmaceuticals, Ltd. | 6.5 Million USD | -2514.934% |
| Spero Therapeutics, Inc. | 75.49 Million USD | -125.321% |
| Artelo Biosciences, Inc. | 1.02 Million USD | -16560.921% |
| 2seventy bio, Inc. | 310.12 Million USD | 45.149% |
| ADMA Biologics, Inc. | 193.97 Million USD | 12.305% |
| Clene Inc. | 38.95 Million USD | -336.723% |
| Capricor Therapeutics, Inc. | 36.13 Million USD | -370.785% |
| Boundless Bio, Inc. Common Stock | 256.97 Million USD | 33.804% |
| GeoVax Labs, Inc. | 3.51 Million USD | -4732.777% |
| Recursion Pharmaceuticals, Inc. | 190.26 Million USD | 10.593% |
| Citius Pharmaceuticals, Inc. | 12.17 Million USD | -1296.656% |
| Contineum Therapeutics, Inc. Class A Common Stock | 198.32 Million USD | 14.226% |
| Relmada Therapeutics, Inc. | 12.19 Million USD | -1294.922% |
| Finch Therapeutics Group, Inc. | 48.11 Million USD | -253.574% |
| ALX Oncology Holdings Inc. | 52.84 Million USD | -221.924% |
| Vir Biotechnology, Inc. | 369.85 Million USD | 54.007% |
| Evaxion Biotech A/S | 17.61 Million USD | -865.564% |
| Ocular Therapeutix, Inc. | 160.92 Million USD | -5.704% |
| Verve Therapeutics, Inc. | 153.18 Million USD | -11.047% |
| Trevena, Inc. | 48.26 Million USD | -252.468% |
| Surrozen, Inc. | 8.14 Million USD | -1988.496% |
| Tyra Biosciences, Inc. | 21.59 Million USD | -687.719% |
| Cingulate Inc. | 10.36 Million USD | -1541.832% |
| Galmed Pharmaceuticals Ltd. | 2.75 Million USD | -6085.745% |
| Unity Biotechnology, Inc. | 37.29 Million USD | -356.151% |
| Tenax Therapeutics, Inc. | 3.58 Million USD | -4642.982% |
| Terns Pharmaceuticals, Inc. | 13.15 Million USD | -1193.597% |
| ACADIA Pharmaceuticals Inc. | 317.2 Million USD | 46.372% |
| Connect Biopharma Holdings Limited | 24.84 Million USD | -584.567% |
| Clearmind Medicine Inc. | 3.61 Million USD | -4612.123% |
| Kronos Bio, Inc. | 54.2 Million USD | -213.847% |
| Bolt Biotherapeutics, Inc. | 47.04 Million USD | -261.601% |
| CERo Therapeutics Holdings, Inc. | 22.75 Million USD | -647.408% |
| Viking Therapeutics, Inc. | 20.07 Million USD | -747.531% |
| Statera Biopharma, Inc. | 22.67 Million USD | -650.153% |
| ImmunityBio, Inc. | 1.09 Billion USD | 84.399% |
| Korro Bio, Inc. | 51.75 Million USD | -228.698% |
| Kineta, Inc. | 7.22 Million USD | -2255.414% |
| BioVie Inc. | 9.7 Million USD | -1653.306% |
| Codexis, Inc. | 49.94 Million USD | -240.584% |
| Celularity Inc. | 102.92 Million USD | -65.267% |
| Crinetics Pharmaceuticals, Inc. | 96.24 Million USD | -76.741% |
| Celcuity Inc. | 51.45 Million USD | -230.627% |
| Virax Biolabs Group Limited | 345.19 Thousand USD | -49178.956% |
| Cibus, Inc. | 206.11 Million USD | 17.47% |
| Eledon Pharmaceuticals, Inc. | 42.47 Million USD | -300.49% |
| eFFECTOR Therapeutics, Inc. | 26.33 Million USD | -545.841% |
| IN8bio, Inc. | 8.77 Million USD | -1839.216% |
| Kodiak Sciences Inc. | 213.59 Million USD | 20.358% |
| Annexon, Inc. | 47.11 Million USD | -261.026% |
| Adverum Biotechnologies, Inc. | 89.54 Million USD | -89.978% |
| Assembly Biosciences, Inc. | 96.37 Million USD | -76.512% |
| Avalo Therapeutics, Inc. | 13.68 Million USD | -1142.662% |
| Ionis Pharmaceuticals, Inc. | 2.6 Billion USD | 93.466% |
| Eyenovia, Inc. | 19.78 Million USD | -759.988% |
| Puma Biotechnology, Inc. | 177.08 Million USD | 3.94% |
| Conduit Pharmaceuticals Inc. | 7.68 Million USD | -2114.66% |
| Xilio Therapeutics, Inc. | 24.09 Million USD | -605.872% |
| Arcellx, Inc. | 339.75 Million USD | 49.932% |
| Cardiff Oncology, Inc. | 11.89 Million USD | -1329.719% |
| Enanta Pharmaceuticals, Inc. | 245.54 Million USD | 30.721% |
| Regulus Therapeutics Inc. | 9.56 Million USD | -1678.814% |
| Moolec Science SA | 13.94 Million USD | -1119.818% |
| Acumen Pharmaceuticals, Inc. | 43.15 Million USD | -294.207% |
| Geron Corporation | 146.12 Million USD | -16.411% |
| LAVA Therapeutics N.V. | 50.53 Million USD | -236.634% |
| Royalty Pharma plc | 6.29 Billion USD | 97.299% |
| Atea Pharmaceuticals, Inc. | 39.77 Million USD | -327.665% |
| Greenwich LifeSciences, Inc. | 294.4 Thousand USD | -57680.072% |
| TFF Pharmaceuticals, Inc. | 2.46 Million USD | -6814.167% |
| Mersana Therapeutics, Inc. | 189.15 Million USD | 10.07% |
| Humacyte, Inc. | 114.67 Million USD | -48.337% |
| Structure Therapeutics Inc. | 29.05 Million USD | -485.549% |
| 89bio, Inc. | 59.96 Million USD | -183.688% |
| PMV Pharmaceuticals, Inc. | 26.46 Million USD | -542.814% |
| Avenue Therapeutics, Inc. | 1.19 Million USD | -14123.077% |
| Genelux Corporation | 8.42 Million USD | -1920.285% |
| Trevi Therapeutics, Inc. | 6.85 Million USD | -2381.155% |
| Lexicon Pharmaceuticals, Inc. | 136.31 Million USD | -24.787% |
| Notable Labs, Ltd. | 4.42 Million USD | -3742.512% |
| Liquidia Corporation | 73.13 Million USD | -132.585% |
| Mustang Bio, Inc. | 17.61 Million USD | -865.48% |
| Immunovant, Inc. | 48.95 Million USD | -247.478% |
| Quantum-Si incorporated | 26.63 Million USD | -538.759% |
| Arbutus Biopharma Corporation | 38.38 Million USD | -343.186% |
| DiaMedica Therapeutics Inc. | 3.1 Million USD | -5382.05% |
| Vera Therapeutics, Inc. | 73.86 Million USD | -130.308% |
| Acasti Pharma Inc. | 11.55 Million USD | -1371.904% |
| MiNK Therapeutics, Inc. | 22.6 Million USD | -652.433% |
| Pasithea Therapeutics Corp. | 2.71 Million USD | -6157.638% |
| Xenon Pharmaceuticals Inc. | 36.87 Million USD | -361.285% |
| Elevai Labs, Inc. Common Stock | 1.36 Million USD | -12381.858% |
| NeuroBo Pharmaceuticals, Inc. | 6.09 Million USD | -2690.486% |
| Tempest Therapeutics, Inc. | 24.83 Million USD | -584.953% |
| Soleno Therapeutics, Inc. | 23.18 Million USD | -633.73% |
| PepGen Inc. | 34.63 Million USD | -391.202% |
| Moleculin Biotech, Inc. | 12.14 Million USD | -1300.758% |
| United Therapeutics Corporation | 1.18 Billion USD | 85.611% |
| Nuvectis Pharma, Inc. | 6.98 Million USD | -2335.682% |
| Solid Biosciences Inc. | 38.45 Million USD | -342.321% |
| BriaCell Therapeutics Corp. | 8.55 Million USD | -1887.895% |
| Immuneering Corporation | 12 Million USD | -1316.58% |
| Lixte Biotechnology Holdings, Inc. | 313.85 Thousand USD | -54099.033% |
| Silo Pharma, Inc. | 1.56 Million USD | -10739.945% |
| Belite Bio, Inc | 4.21 Million USD | -3939.611% |
| XOMA Corporation | 145.58 Million USD | -16.848% |
| ARS Pharmaceuticals, Inc. | 2.42 Million USD | -6906.096% |
| Bionomics Limited | 10.15 Million USD | -1574.502% |
| Apogee Therapeutics, Inc. | 21.49 Million USD | -691.531% |
| Alpha Tau Medical Ltd. | 22.91 Million USD | -642.408% |
| uniQure N.V. | 624.01 Million USD | 72.74% |
| Cassava Sciences, Inc. | 14.19 Million USD | -1098.366% |
| Estrella Immunopharma, Inc. | 180.7 Thousand USD | -94037.83% |
| Poseida Therapeutics, Inc. | 170.18 Million USD | 0.045% |
| Forte Biosciences, Inc. | 3.66 Million USD | -4540.153% |
| Anebulo Pharmaceuticals, Inc. | 260.58 Thousand USD | -65179.777% |
| Enlivex Therapeutics Ltd. | 6.74 Million USD | -2421.239% |
| Conduit Pharmaceuticals Inc. | 7.68 Million USD | -2114.66% |
| SeaStar Medical Holding Corporation | 17.38 Million USD | -878.588% |
| FibroBiologics, Inc. Common Stock | 10.56 Million USD | -1509.652% |
| Altimmune, Inc. | 16.54 Million USD | -928.402% |
| Amicus Therapeutics, Inc. | 617.7 Million USD | 72.461% |
| Alpha Tau Medical Ltd. | 22.91 Million USD | -642.408% |
| Compugen Ltd. | 55.77 Million USD | -204.99% |
| Peak Bio, Inc. | 20.75 Million USD | -719.665% |
| Zevra Therapeutics, Inc. | 110.46 Million USD | -53.995% |
| Benitec Biopharma Inc. | 4.96 Million USD | -3328.214% |
| Spyre Therapeutics, Inc. | 157.84 Million USD | -7.77% |
| NKGen Biotech, Inc. Common Stock | 75.17 Million USD | -126.286% |
| Zura Bio Limited | 21.29 Million USD | -698.929% |
| PolyPid Ltd. | 17.46 Million USD | -873.826% |
| Aileron Therapeutics, Inc. | 112.39 Million USD | -51.343% |
| NKGen Biotech, Inc. Warrants | 75.17 Million USD | -126.286% |
| Instil Bio, Inc. | 99.8 Million USD | -70.447% |
| argenx SE | 444.95 Million USD | 61.769% |
| Immunome, Inc. | 28.65 Million USD | -493.579% |
| Compass Therapeutics, Inc. | 8.33 Million USD | -1940.398% |
| Verona Pharma plc | 58.84 Million USD | -189.098% |
| enGene Holdings Inc. Warrants | 14.47 Million USD | -1075.347% |
| Shattuck Labs, Inc. | 14.85 Million USD | -1044.815% |
| CervoMed Inc. | 2.59 Million USD | -6453.335% |
| LENZ Therapeutics, Inc. | 4.87 Million USD | -3390.111% |
| Plus Therapeutics, Inc. | 12.73 Million USD | -1235.647% |
| Dianthus Therapeutics, Inc. | 10.53 Million USD | -1514.694% |
| Moolec Science SA | 13.94 Million USD | -1119.818% |
| Enveric Biosciences, Inc. | 2.34 Million USD | -7158.703% |
| Inovio Pharmaceuticals, Inc. | 55.59 Million USD | -205.976% |
| AnaptysBio, Inc. | 364.28 Million USD | 53.304% |
| Design Therapeutics, Inc. | 11.95 Million USD | -1322.784% |
| Leap Therapeutics, Inc. | 12.68 Million USD | -1241.123% |
| NeurAxis, Inc. | 1.91 Million USD | -8793.425% |
| Seelos Therapeutics, Inc. | 38.92 Million USD | -336.981% |
| Lumos Pharma, Inc. | 13.33 Million USD | -1175.842% |
| Achilles Therapeutics plc | 19.08 Million USD | -791.224% |
| enGene Holdings Inc. Common Stock | 14.47 Million USD | -1075.347% |
| 180 Life Sciences Corp. | 5.38 Million USD | -3057.628% |
| Opiant Pharmaceuticals, Inc. | 23.58 Million USD | -621.164% |
| CERo Therapeutics Holdings, Inc. | 22.75 Million USD | -647.408% |
| Nutriband Inc. | 1.07 Million USD | -15666.522% |
| ORIC Pharmaceuticals, Inc. | 30.59 Million USD | -455.945% |
| CG Oncology, Inc. Common stock | 14.51 Million USD | -1072.269% |
| Fractyl Health, Inc. Common Stock | 401.27 Million USD | 57.608% |
| Rani Therapeutics Holdings, Inc. | 32.47 Million USD | -423.844% |
| MoonLake Immunotherapeutics | 13.04 Million USD | -1203.6% |
| Palisade Bio, Inc. | 2.73 Million USD | -6110.588% |
| Tourmaline Bio, Inc. | 5.25 Million USD | -3138.302% |
| Beam Therapeutics Inc. | 478.38 Million USD | 64.441% |
| Neurogene Inc. | 36.54 Million USD | -365.424% |
| Mirum Pharmaceuticals, Inc. | 397.95 Million USD | 57.254% |
| AEON Biopharma, Inc. | 159.88 Million USD | -6.391% |
| CARGO Therapeutics, Inc. Common Stock | 47.65 Million USD | -256.995% |
| Sesen Bio, Inc. | 30.98 Million USD | -449.019% |
| Enliven Therapeutics, Inc. | 25.96 Million USD | -555.244% |
| Kiora Pharmaceuticals, Inc. | 7.6 Million USD | -2137.611% |
| Iovance Biotherapeutics, Inc. | 195.73 Million USD | 13.094% |
| Taysha Gene Therapies, Inc. | 192.05 Million USD | 11.428% |
| Athira Pharma, Inc. | 30.05 Million USD | -465.951% |
| Vaccinex, Inc. | 5.94 Million USD | -2762.807% |
| HCW Biologics Inc. | 15.05 Million USD | -1030.14% |
| XOMA Corporation | 145.58 Million USD | -16.848% |
| Nektar Therapeutics | 267.04 Million USD | 36.3% |
| Arvinas, Inc. | 644.6 Million USD | 73.61% |
| Tevogen Bio Holdings Inc. | 17.73 Million USD | -859.267% |
| Merus N.V. | 102.15 Million USD | -66.526% |
| Omega Therapeutics, Inc. | 146.35 Million USD | -16.234% |
| Quince Therapeutics, Inc. | 95.12 Million USD | -78.835% |
| Rezolute, Inc. | 11.73 Million USD | -1349.702% |
| Clene Inc. | 38.95 Million USD | -336.723% |
| Indaptus Therapeutics, Inc. | 2.84 Million USD | -5874.194% |
| BeyondSpring Inc. | 48.26 Million USD | -252.417% |
| Synlogic, Inc. | 32.89 Million USD | -417.124% |
| Allarity Therapeutics, Inc. | 14.61 Million USD | -1064.087% |
| Phio Pharmaceuticals Corp. | 1.63 Million USD | -10310.526% |
| Peak Bio, Inc. | 20.75 Million USD | -719.665% |
| Werewolf Therapeutics, Inc. | 63.45 Million USD | -168.06% |
| Krystal Biotech, Inc. | 39.71 Million USD | -328.333% |
| Karyopharm Therapeutics Inc. | 376.64 Million USD | 54.836% |
| SpringWorks Therapeutics, Inc. | 99.56 Million USD | -70.844% |
| Lipella Pharmaceuticals Inc. | 432.72 Thousand USD | -39210.788% |
| MannKind Corporation | 721.36 Million USD | 76.419% |
| Ikena Oncology, Inc. | 22.33 Million USD | -661.621% |
| Cyclerion Therapeutics, Inc. | 2.08 Million USD | -8054.746% |
| Gyre Therapeutics, Inc. | 102.59 Million USD | -65.813% |
| Gossamer Bio, Inc. | 249.14 Million USD | 31.724% |
| CohBar, Inc. | 1.03 Million USD | -16357.212% |
| Cognition Therapeutics, Inc. | 10.68 Million USD | -1491.43% |
| NRx Pharmaceuticals, Inc. | 19.04 Million USD | -793.049% |
| Legend Biotech Corporation | 589.93 Million USD | 71.165% |
| Mural Oncology plc | 37.92 Million USD | -348.502% |
| Biora Therapeutics, Inc. | 132.63 Million USD | -28.252% |
| PaxMedica, Inc. Common Stock | 2.29 Million USD | -7311.041% |
| Disc Medicine, Inc. | 22.87 Million USD | -643.642% |
| Champions Oncology, Inc. | 28.03 Million USD | -506.77% |
| REGENXBIO Inc. | 262.22 Million USD | 35.13% |
| Ensysce Biosciences, Inc. | 3.35 Million USD | -4963.715% |
| Anavex Life Sciences Corp. | 12.53 Million USD | -1257.172% |
| Cellectar Biosciences, Inc. | 13.43 Million USD | -1166.474% |
| Edgewise Therapeutics, Inc. | 21.2 Million USD | -702.207% |
| Vaxart, Inc. | 34.02 Million USD | -399.95% |
| PharmaCyte Biotech, Inc. | 20.38 Million USD | -734.302% |
| Aldeyra Therapeutics, Inc. | 28.53 Million USD | -496.203% |
| Cellectis S.A. | 249.57 Million USD | 31.841% |
| Longeveron Inc. | 5.33 Million USD | -3087.334% |
| Repare Therapeutics Inc. | 41.81 Million USD | -306.772% |
| Sarepta Therapeutics, Inc. | 2.4 Billion USD | 92.928% |
| Inozyme Pharma, Inc. | 60.36 Million USD | -181.785% |
| Revolution Medicines, Inc. | 262.39 Million USD | 35.172% |
| Nymox Pharmaceutical Corporation | 2.1 Million USD | -7973.469% |
| Third Harmonic Bio, Inc. | 8.62 Million USD | -1872.038% |
| ArriVent BioPharma, Inc. Common Stock | 11.8 Million USD | -1341.471% |
| AN2 Therapeutics, Inc. | 14.04 Million USD | -1111.337% |
| Anixa Biosciences, Inc. | 2.15 Million USD | -7808.322% |
| Vertex Pharmaceuticals Incorporated | 5.14 Billion USD | 96.697% |
| Denali Therapeutics Inc. | 122.96 Million USD | -38.341% |
| Revelation Biosciences, Inc. | 5.56 Million USD | -2956.806% |
| Veru Inc. | 32.81 Million USD | -418.421% |
| Corvus Pharmaceuticals, Inc. | 6.86 Million USD | -2376.459% |
| Cingulate Inc. | 10.36 Million USD | -1541.832% |
| Passage Bio, Inc. | 39.26 Million USD | -333.264% |
| Context Therapeutics Inc. | 4.19 Million USD | -3958.196% |
| Exicure, Inc. | 8.54 Million USD | -1889.8% |
| Day One Biopharmaceuticals, Inc. | 29.5 Million USD | -476.481% |
| Oramed Pharmaceuticals Inc. | 10.48 Million USD | -1522.239% |
| Scinai Immunotherapeutics Ltd. | 22.04 Million USD | -671.78% |
| Rhythm Pharmaceuticals, Inc. | 162.98 Million USD | -4.37% |
| Nuvalent, Inc. | 31.82 Million USD | -434.544% |
| ABVC BioPharma, Inc. | 6.36 Million USD | -2573.97% |
| Carisma Therapeutics, Inc. | 63.02 Million USD | -169.918% |
| Unicycive Therapeutics, Inc. | 18 Million USD | -845.044% |
| OmniAb, Inc. | 87.4 Million USD | -94.632% |
| Anew Medical, Inc. | 8.24 Million USD | -1963.967% |
| Fennec Pharmaceuticals Inc. | 38.28 Million USD | -344.273% |
| Lipocine Inc. | 2.63 Million USD | -6363.981% |
| Lexeo Therapeutics, Inc. Common Stock | 26.27 Million USD | -547.488% |
| Nautilus Biotechnology, Inc. | 40.21 Million USD | -323.028% |
| SAB Biotherapeutics, Inc. | 26.64 Million USD | -538.5% |
| G1 Therapeutics, Inc. | 86.15 Million USD | -97.446% |
| Bellerophon Therapeutics, Inc. | 5.4 Million USD | -3049.565% |
| Sage Therapeutics, Inc. | 82.74 Million USD | -105.576% |
| Ocugen, Inc. | 23.98 Million USD | -609.286% |
| Mind Medicine (MindMed) Inc. | 46.4 Million USD | -266.557% |
| Q32 Bio Inc. | 233.12 Million USD | 27.032% |
| Brainstorm Cell Therapeutics Inc. | 9.06 Million USD | -1776.329% |
| Alumis Inc. Common Stock | 53.5 Million USD | -217.947% |
| Equillium, Inc. | 27.95 Million USD | -508.463% |
| Kyverna Therapeutics, Inc. | 206.59 Million USD | 17.66% |
| Coya Therapeutics, Inc. | 5.62 Million USD | -2923.247% |
| CNS Pharmaceuticals, Inc. | 6.13 Million USD | -2673.665% |
| Galera Therapeutics, Inc. | 157.32 Million USD | -8.125% |
| Evelo Biosciences, Inc. | 69.43 Million USD | -144.996% |
| Comera Life Sciences Holdings, Inc. | 9.97 Million USD | -1605.48% |
| Dominari Holdings Inc. | 4.63 Million USD | -3570.076% |
| Edesa Biotech, Inc. | 1.84 Million USD | -9136.782% |
| vTv Therapeutics Inc. | 29.56 Million USD | -475.331% |
| Bio-Techne Corporation | 744.34 Million USD | 77.146% |
| Agios Pharmaceuticals, Inc. | 126.09 Million USD | -34.9% |
| Harmony Biosciences Holdings, Inc. | 344.45 Million USD | 50.615% |
| Prelude Therapeutics Incorporated | 40.57 Million USD | -319.243% |
| Candel Therapeutics, Inc. | 28.95 Million USD | -487.45% |
| iTeos Therapeutics, Inc. | 92.36 Million USD | -84.179% |
| Nkarta, Inc. | 105.6 Million USD | -61.087% |
| BioCardia, Inc. | 4.59 Million USD | -3606.057% |
| Iterum Therapeutics plc | 32.66 Million USD | -420.813% |